Rafivirumab

Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails[1][2][3].

Product Specifications

CAS Number

[944548-37-2]

Product Name Alternative

CR57

UNSPSC

12352203

Target

RABV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/rafivirumab.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Rafivirumab]

Molecular Weight

(145.76 kDa)

References & Citations

[1]Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35 (7) :2131-45. |[2]Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2 (3) :48. |[3]Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12 (1) :9403.